<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients receive education before implantable cardioverter defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) implantation </plain></SENT>
<SENT sid="1" pm="."><plain>Patients' understanding of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy requires investigation </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A retrospective cohort study was carried out at two implant centers where patients are educated during a consenting process pre-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation </plain></SENT>
<SENT sid="3" pm="."><plain>Questionnaires examining understanding of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy were completed during telephone interviews of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Of 75 patients interviewed, 62 (83%) were male </plain></SENT>
<SENT sid="5" pm="."><plain>The median age at time of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation was 64 years (standard deviation [SD] = 9.4; range: 29-82 years) </plain></SENT>
<SENT sid="6" pm="."><plain>The median interval from implantation to interview was 3 years (SD = 1.9; range: 0.1-9.0 years) </plain></SENT>
<SENT sid="7" pm="."><plain>Despite 83% (62 of 75) claiming to understand the reason for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation, no patient suggested <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> termination when describing the indication </plain></SENT>
<SENT sid="8" pm="."><plain>Of shock recipients, 60% (12 of 20) felt poorly prepared for shock therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Of patients who experienced a device-related complication, 83% (10 of 12) reported feeling inadequately forewarned of complications </plain></SENT>
<SENT sid="10" pm="."><plain>Excluding patients with cardiac resynchronization therapy defibrillators (n = 6), 65% (45 of 69), 52% (36 of 69), 50% (35 of 69), and 61% (42 of 69) believe their <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> reduces risk of <z:e sem="disease" ids="C0027051" disease_type="Disease or Syndrome" abbrv="MR|mi|AMI">heart attack</z:e> and improves breathing, exercise capacity, and heart function, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Ninety-three percent (70 of 75) are satisfied with their decision to accept <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy </plain></SENT>
<SENT sid="12" pm="."><plain>Only 12% (9 of 75) believe they will want to inactivate therapies in setting of <z:e sem="disease" ids="C0679247" disease_type="Disease or Syndrome" abbrv="">terminal illness</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Despite preimplantation education, patient comprehension of the risks and benefits of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy is poor </plain></SENT>
<SENT sid="14" pm="."><plain>Patients' expectations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy may be inappropriate </plain></SENT>
<SENT sid="15" pm="."><plain>Education strategies before and after implantation require improvement </plain></SENT>
</text></document>